CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Kisqali for Metastatic Breast Cancer – Details

Project Number PC0112-000
Brand Name Kisqali
Generic Name Ribociclib
Strength 200 mg
Tumour Type Breast
Indication Advanced or Metastatic Breast Cancer
Funding Request For the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as an initial endocrine-based therapy
Review Status Complete
Pre Noc Submission Yes
NOC Date March 2, 2018
Manufacturer Novartis Pharmaceuticals Canada Inc.
Sponsor Novartis Pharmaceuticals Canada Inc.
Submission Date October 17, 2017
Submission Deemed Complete November 1, 2017
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ October 31, 2017
Check-point meeting December 12, 2017
pERC Meeting March 15, 2018
Initial Recommendation Issued March 29, 2018
Feedback Deadline ‡ April 13, 2018
Final Recommendation Issued April 18, 2018
Notification to Implement Issued May 3, 2018
Therapeutic Area Advanced or Metastatic Breast Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.